• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对CYP3A4的利托那韦样抑制剂中更大侧链基团功能以及侧链/端基相互作用的评估。

Evaluation of Larger Side-Group Functionalities and the Side/End-Group Interplay in Ritonavir-Like Inhibitors of CYP3A4.

作者信息

Samuels Eric R, Sevrioukova Irina F

机构信息

Department of Pharmaceutical Sciences, University of California, Irvine, California, USA.

Department of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.

出版信息

Chem Biol Drug Des. 2025 Jan;105(1):e70043. doi: 10.1111/cbdd.70043.

DOI:10.1111/cbdd.70043
PMID:39792691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11749023/
Abstract

A new series of 13 ritonavir-like inhibitors of human drug-metabolizing CYP3A4 was rationally designed to study the R side-group and R end-group interplay when the R side-group is represented by phenyl. Spectral, functional, and structural characterization showed no improvement in the binding affinity and inhibitory potency of R/R-phenyl inhibitors upon elongation and/or fluorination of R-Boc (tert-butyloxycarbonyl) or its replacement with benzenesulfonyl. When R is pyridine, the impact of R-phenyl-to-indole/naphthalene substitution was multidirectional and highly dependent on side-group stereo configuration. Overall, the R-naphthalene/R-pyridine containing 2f (R/S) was the series lead compound and one of the strongest binders/inhibitors designed thus far (K = 0.009 μM; IC = 0.10 μM). Introduction of a larger biphenyl or fluorene as R did not lead to any improvements. Contrarily, fluorene-containing 13 was the series weakest binder and inhibitor (K = 0.734 μM; IC = 1.32 μM), implying that the fluorene moiety is too large to allow unrestricted access to the active site. The R-biphenyl, however, can switch positions with R-Boc to enable heme ligation. Thus, for small and chemically simple end-groups such as Boc and pyridine, the R/R interplay could lead to conformational rearrangement that would be difficult to foresee without structural information.

摘要

合理设计了一系列新的13种类似利托那韦的人药物代谢CYP3A4抑制剂,以研究当R侧基由苯基表示时R侧基和R端基的相互作用。光谱、功能和结构表征表明,在R-Boc(叔丁氧羰基)延长和/或氟化或用苯磺酰基取代后,R/R-苯基抑制剂的结合亲和力和抑制效力没有改善。当R为吡啶时,R-苯基到吲哚/萘取代的影响是多方向的,并且高度依赖于侧基立体构型。总体而言,含R-萘/R-吡啶的2f(R/S)是该系列的先导化合物,也是迄今为止设计的最强结合剂/抑制剂之一(K = 0.009 μM;IC = 0.10 μM)。引入更大的联苯或芴作为R并没有带来任何改善。相反,含芴的13是该系列中最弱的结合剂和抑制剂(K = 0.734 μM;IC = 1.32 μM),这意味着芴部分太大,无法无限制地进入活性位点。然而,R-联苯可以与R-Boc交换位置以实现血红素连接。因此,对于诸如Boc和吡啶等小且化学结构简单的端基,R/R相互作用可能导致构象重排,而没有结构信息很难预见这种重排。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/d270b015af23/nihms-2047257-f0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/c44b4af90a71/nihms-2047257-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/ebab5b896ff0/nihms-2047257-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/725ad58ff441/nihms-2047257-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/998a7c40bc7b/nihms-2047257-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/9456b0e2ae37/nihms-2047257-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/66944889a6dd/nihms-2047257-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/c491da419b9f/nihms-2047257-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/04a90d648c16/nihms-2047257-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/1edf46228e26/nihms-2047257-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/6771a9f44373/nihms-2047257-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/273118056b6e/nihms-2047257-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/71fb697424a0/nihms-2047257-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/578fcb86ce91/nihms-2047257-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/1359722ea6c4/nihms-2047257-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/de2785ccdd70/nihms-2047257-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/2ba38274662e/nihms-2047257-f0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/d270b015af23/nihms-2047257-f0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/c44b4af90a71/nihms-2047257-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/ebab5b896ff0/nihms-2047257-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/725ad58ff441/nihms-2047257-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/998a7c40bc7b/nihms-2047257-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/9456b0e2ae37/nihms-2047257-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/66944889a6dd/nihms-2047257-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/c491da419b9f/nihms-2047257-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/04a90d648c16/nihms-2047257-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/1edf46228e26/nihms-2047257-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/6771a9f44373/nihms-2047257-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/273118056b6e/nihms-2047257-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/71fb697424a0/nihms-2047257-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/578fcb86ce91/nihms-2047257-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/1359722ea6c4/nihms-2047257-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/de2785ccdd70/nihms-2047257-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/2ba38274662e/nihms-2047257-f0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa52/11749023/d270b015af23/nihms-2047257-f0018.jpg

相似文献

1
Evaluation of Larger Side-Group Functionalities and the Side/End-Group Interplay in Ritonavir-Like Inhibitors of CYP3A4.对CYP3A4的利托那韦样抑制剂中更大侧链基团功能以及侧链/端基相互作用的评估。
Chem Biol Drug Des. 2025 Jan;105(1):e70043. doi: 10.1111/cbdd.70043.
2
Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.基于合理设计的利托那韦类似物的构效关系:侧基立体化学、头基间距和骨架组成对与 CYP3A4 相互作用的影响。
Biochemistry. 2019 Apr 16;58(15):2077-2087. doi: 10.1021/acs.biochem.9b00156. Epub 2019 Apr 3.
3
Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities.合理设计的利托那韦类似物对人 CYP3A4 的抑制作用:侧基功能的影响和相互作用。
Mol Pharm. 2018 Jan 2;15(1):279-288. doi: 10.1021/acs.molpharmaceut.7b00957. Epub 2017 Dec 12.
4
An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.侧基疏水性的增加在很大程度上提高了 ritonavir 样 CYP3A4 抑制剂的效力。
Bioorg Med Chem. 2020 Mar 15;28(6):115349. doi: 10.1016/j.bmc.2020.115349. Epub 2020 Jan 31.
5
Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.CYP3A4 抑制剂的合理设计:在利托那韦类似物中引入单原子连接子延伸,显著提高结合强度。
Int J Mol Sci. 2021 Jan 16;22(2):852. doi: 10.3390/ijms22020852.
6
Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir.CYP3A4 与抑制剂考比司他的相互作用:结构和机制的见解,并与利托那韦进行比较。
Arch Biochem Biophys. 2024 Aug;758:110071. doi: 10.1016/j.abb.2024.110071. Epub 2024 Jun 22.
7
Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment.CYP3A4 与合理设计的利托那韦类似物的相互作用:对血红素配体基团和末端吡啶连接物施加的空间位阻的影响。
Int J Mol Sci. 2022 Jun 30;23(13):7291. doi: 10.3390/ijms23137291.
8
Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.利托那韦类似物作为一种用于解读细胞色素P450 3A4抑制机制的探针。
Curr Top Med Chem. 2014;14(11):1348-55. doi: 10.2174/1568026614666140506120647.
9
Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.吡啶取代的去羟肌苷是一种比利托那韦更有效的细胞色素 P450 3A4 抑制剂。
J Med Chem. 2013 May 9;56(9):3733-41. doi: 10.1021/jm400288z. Epub 2013 Apr 26.
10
Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.利用利托那韦类似物解析细胞色素 P450 3A4 配体相互作用。
Biochemistry. 2013 Jul 2;52(26):4474-81. doi: 10.1021/bi4005396. Epub 2013 Jun 20.

引用本文的文献

1
How Plant Polyhydroxy Flavonoids Can Hinder the Metabolism of Cytochrome 3A4.植物多羟基黄酮如何阻碍细胞色素3A4的代谢。
Biomedicines. 2025 Mar 7;13(3):655. doi: 10.3390/biomedicines13030655.

本文引用的文献

1
Synthesis and anticancer properties of a hybrid molecule with the testosterone and estradiol head-groups.睾酮和雌二醇头基杂化分子的合成及抗癌性能。
Steroids. 2024 Sep;209:109469. doi: 10.1016/j.steroids.2024.109469. Epub 2024 Jul 9.
2
Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir.CYP3A4 与抑制剂考比司他的相互作用:结构和机制的见解,并与利托那韦进行比较。
Arch Biochem Biophys. 2024 Aug;758:110071. doi: 10.1016/j.abb.2024.110071. Epub 2024 Jun 22.
3
Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment.
CYP3A4 与合理设计的利托那韦类似物的相互作用:对血红素配体基团和末端吡啶连接物施加的空间位阻的影响。
Int J Mol Sci. 2022 Jun 30;23(13):7291. doi: 10.3390/ijms23137291.
4
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.将 SJ733(一种口服的疟原虫 ATP4 抑制剂)与药代动力学增强剂考比司他结合:抗疟药物研发的创新方法。
EBioMedicine. 2022 Jun;80:104065. doi: 10.1016/j.ebiom.2022.104065. Epub 2022 May 19.
5
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.通过 CYP3A 抑制来有意调节伊布替尼的药代动力学。
Cancer Res Commun. 2021 Nov;1(2):79-89. doi: 10.1158/2767-9764.crc-21-0076. Epub 2021 Nov 9.
6
Innovative C-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4.创新的 C-对称睾酮和雄烯二酮二聚体:设计、合成、对前列腺癌细胞系的生物评价以及与重组 CYP3A4 的结合研究。
Eur J Med Chem. 2021 Aug 5;220:113496. doi: 10.1016/j.ejmech.2021.113496. Epub 2021 Apr 24.
7
Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.CYP3A4 抑制剂的合理设计:在利托那韦类似物中引入单原子连接子延伸,显著提高结合强度。
Int J Mol Sci. 2021 Jan 16;22(2):852. doi: 10.3390/ijms22020852.
8
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.首个使用丙肝病毒蛋白酶抑制剂达诺普韦治疗新冠肺炎患者的临床研究。
Medicine (Baltimore). 2020 Nov 25;99(48):e23357. doi: 10.1097/MD.0000000000023357.
9
An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.侧基疏水性的增加在很大程度上提高了 ritonavir 样 CYP3A4 抑制剂的效力。
Bioorg Med Chem. 2020 Mar 15;28(6):115349. doi: 10.1016/j.bmc.2020.115349. Epub 2020 Jan 31.
10
Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin.细胞色素 P450 3A4 与自杀底物米贝地尔、阿扎美伦和 6',7'-二羟基去氢川陈皮素相互作用的结构见解。
Int J Mol Sci. 2019 Aug 30;20(17):4245. doi: 10.3390/ijms20174245.